My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 204

    1.

    Therapeutic strategies based on glucagon-like peptide 1.

    Deacon CF.

    Diabetes. 2004 Sep;53(9):2181-9. Review.PMID: 15331525 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.

    Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC.

    Bioconjug Chem. 2005 Mar-Apr;16(2):377-82.PMID: 15769092 [PubMed - indexed for MEDLINE]Related articles

    3.

    Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

    Holst JJ, Deacon CF.

    Diabetes. 1998 Nov;47(11):1663-70. Review.PMID: 9792533 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.

    Baggio LL, Drucker DJ.

    Treat Endocrinol. 2002;1(2):117-25. Review.PMID: 15765627 [PubMed - indexed for MEDLINE]Related articles

    5.

    Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

    Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR.

    Biol Chem. 2004 Feb;385(2):169-77.PMID: 15101559 [PubMed - indexed for MEDLINE]Related articles

    6.

    Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

    Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C.

    Diabetes Metab. 2005 Jun;31(3 Pt 1):233-42. Review.PMID: 16142014 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

    Green BD, Gault VA, O'harte FP, Flatt PR.

    Curr Pharm Des. 2004;10(29):3651-62. Review.PMID: 15579061 [PubMed - indexed for MEDLINE]Related articles

    8.

    Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.

    Drucker DJ.

    Curr Pharm Des. 2001 Sep;7(14):1399-412. Review.PMID: 11472275 [PubMed - indexed for MEDLINE]Related articles

    9.

    Enhancing incretin action for the treatment of type 2 diabetes.

    Drucker DJ.

    Diabetes Care. 2003 Oct;26(10):2929-40. Review.PMID: 14514604 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.

    O'Harte FP, Mooney MH, Kelly CM, McKillop AM, Flatt PR.

    Regul Pept. 2001 Jan 12;96(3):95-104.PMID: 11111014 [PubMed - indexed for MEDLINE]Related articles

    11.

    Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.

    Holst JJ.

    Adv Exp Med Biol. 2003;524:263-79. Review.PMID: 12675249 [PubMed - indexed for MEDLINE]Related articles

    12.

    Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.

    Gallwitz B.

    Diabetes Technol Ther. 2005 Aug;7(4):651-7. Review.PMID: 16120042 [PubMed - indexed for MEDLINE]Related articles

    13.

    The potential role of glucagon-like peptide 1 in diabetes.

    Meier JJ, Nauck MA.

    Curr Opin Investig Drugs. 2004 Apr;5(4):402-10. Review.PMID: 15134281 [PubMed - indexed for MEDLINE]Related articles

    14.

    N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

    Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FP, Flatt PR.

    J Endocrinol. 2004 Mar;180(3):379-88.PMID: 15012592 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.

    Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP.

    Arch Biochem Biophys. 2004 Aug 15;428(2):136-43.PMID: 15246869 [PubMed - indexed for MEDLINE]Related articles

    16.

    Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

    Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

    Biol Chem. 2003 Dec;384(12):1543-51.PMID: 14719796 [PubMed - indexed for MEDLINE]Related articles

    17.

    Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.

    Mentlein R.

    Expert Opin Investig Drugs. 2005 Jan;14(1):57-64. Review.PMID: 15709922 [PubMed - indexed for MEDLINE]Related articles

    18.

    On the treatment of diabetes mellitus with glucagon-like peptide-1.

    Holst JJ, Deacon C, Toft-Nielsen MB, Bjerre-Knudsen L.

    Ann N Y Acad Sci. 1998 Dec 11;865:336-43. Review.PMID: 9928027 [PubMed - indexed for MEDLINE]Related articles

    19.

    The entero-insular axis: implications for human metabolism.

    Ranganath LR.

    Clin Chem Lab Med. 2008;46(1):43-56. Review.PMID: 18020966 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.

    Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ.

    Diabetologia. 1998 Mar;41(3):271-8.PMID: 9541166 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity